Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
Children's Motrin Cold is a fixed-dose combination oral suspension containing ibuprofen (a nonsteroidal anti-inflammatory drug) and pseudoephedrine hydrochloride (a nasal decongestant). It is indicated for symptomatic relief of cold and flu symptoms in pediatric patients, addressing fever, pain, and nasal congestion. The combination provides dual mechanism relief by reducing inflammation and fever while simultaneously addressing upper respiratory congestion.
Product is in late-stage lifecycle with moderate competitive pressure (30), suggesting team focus is shifting toward lifecycle extension, cost optimization, or transition planning rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on Children's Motrin Cold in its LOE-approaching stage offers limited growth-phase career momentum but strong foundational commercial experience in brand defense, generic strategy, and lifecycle management. Roles are typically focused on maximizing remaining patent life, cost containment, and tactical market share protection rather than expansion or innovation.
Worked on CHILDREN'S MOTRIN COLD at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.